Nevro (NVRO) Tops Q2 EPS by 16c; Guides FY16 Revenue Above Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Nevro Reports Second Quarter 2016 Financial Results
August 8, 2016 4:10 PM EDTREDWOOD CITY, Calif., Aug. 8, 2016 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and six months ended June 30, 2016.
Second Quarter Highlights:
Achieved revenue of $55.4 million in the second quarter of 2016, an increase of 385% as reported, over the same period of the prior year U.S. revenue of $40.6 million for the second quarter of 2016, the fourth full quarter of commercial availability of... More